* Hemoglobin >= . g/dL at baseline (may receive red blood cell [RBC] transfusions)
For patients with solid tumors without known bone marrow involvement: hemoglobin >= . g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin >= . g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin >= . g/dL (may receive red blood cell [RBC] transfusions) for patients with solid tumors without bone marrow involvement
Hemoglobin >= . g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin >=  g/dL ( g/L) within  days prior cycle , day  (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
Hemoglobin >= . gm/dL (may receive RBC transfusions)
Hemoglobin >= . g/dL at baseline (may receive red blood cell [RBC] transfusions)
Hemoglobin >= . g/dL at baseline (may receive red blood cell [RBC] transfusions)
Hemoglobin ? g/dL, with no red blood cell (RBC) transfusions within the prior  days.
Hemoglobin >=  g/dL (not requiring red blood cell [RBC] transfusions)
Hemoglobin . g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin ? . g/dl (red blood cell (RBC) transfusions are permitted)
Hemoglobin >= . g/dl (red blood cell [RBC] transfusions are permitted) must be met during screening (within  days) and also prior to study drug administration on cycle  day 
Hemoglobin >=  g/dL without red blood cell transfusions within  weeks of the initiation of treatment
Hemoglobin >= .g/dl (may receive red blood cell [RBC] transfusions)
Subjects who are not willing to receive red blood cell (RBC) transfusions to treat low hemoglobin levels
Hemoglobin >= . gm/dL (may receive red blood cell count [RBC] transfusions)
Hemoglobin >=  g/dL performed within  days of treatment initiation (red blood cell [RBC] transfusions are OK)
Hemoglobin >=  g/dL (not requiring red blood cell [RBC] transfusions)
Hemoglobin >=  g/dL without red blood cell transfusions within  weeks of the initiation of treatment
Hgb < . g/dL (unless the hemoglobin value has been stable, the subject is cardiovascularly stable, asymptomatic and judged able to withstand the RFA procedure) Note: If clinically indicated, subjects may receive platelets or packed red blood cell (RBC) transfusions and be re-evaluated after condition is treated.
Hemoglobin >=  g/dL ( g/L) (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
Hemoglobin >=  g/dL ( g/L) within  days prior to starting therapy (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
Patients may receive red blood cell (RBC) or platelet transfusions, if clinically indicated, in accordance with institutional guidelines
Hemoglobin >=  g/dL; subjects may receive red blood cell transfusions as clinically indicated per institutional guidelines but screening hemoglobin should be independent of red blood cell transfusion for at least  days prior to cycle  day 
Hemoglobin >=  g/dL; red blood cell transfusions are permitted to meet eligibility criteria
Hemoglobin >= . g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin >= . g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin greater than  g/dL (may have received red blood cell [RBC] transfusions allowed)
For patients with solid tumors without bone marrow involvement: hemoglobin >= . gm/dL (may receive red blood cell [RBC] transfusions)
For patients with solid tumors without known bone marrow involvement: hemoglobin >= . g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin >= . g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin ?  g/dL ( g/L) within  days prior to randomization (subjects may be\n             receiving red blood cell [RBC] transfusions in accordance with institutional\n             guidelines)
Hemoglobin ?  g/dL. Patients may receive red blood cells (RBC) and/or erythropoietin (EPO) and/or platelet transfusions in accordance with institutional guidelines.
Hemoglobin ? g/dL and no red blood cell (RBC) transfusions during the prior  days
Hemoglobin >= . g/dl (may receive red blood cell [RBC] transfusions)
Hemoglobin >  g/dL ( g/L) within  days prior to cycle  day  (subjects may be receiving red blood cell transfusions in accordance with institutional guidelines)
Hemoglobin >=  g/dL ( g/L) within  days prior to initial treatment (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
Hemoglobin >  g/dL ( g/L) within  days of time of consent (subjects may be receiving red blood cell transfusions in accordance with institutional guidelines)
Hemoglobin >= . g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin >= . g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin ?  g/dL (with no RBC transfusions within  days of Screening)
Hemoglobin >= . g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin > . g/dL (patients are allowed to receive transfused red blood cells [RBC] to achieve this level)
Hemoglobin >=  g/dL ( g/L) within  days prior to randomization (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
Hemoglobin >=  g/dl (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
-MMP >= ,/ x ^ red blood cell (RBC) within  days prior to enrollment
worsening hemoglobin should be ? . g/dL decrease from preinjectable HMA (HYPOMETHYLATING AGENT) baseline value in subjects not receiving RBC (RED BLOOD CELL) transfusions
Hemoglobin ? . g/dL (in the absence of red blood cell transfusions in the prior  days)
Hemoglobin >= . g/dL (may receive red blood cell [RBC] transfusions)